Fairness opinions › Acquirers
Hologic: healthcare acquisitions with fairness opinions
2 public-company targets, 2012-2017, $5.4B combined enterprise value. The multiples Hologic paid and the banker analyses behind each target board's recommendation.
Deals
2
Median EV / EBITDA paid
18.9x
Median EV / revenue paid
4.59x
| Announced | Target | Acquirer | Segment | EV | EV/EBITDA | EV/Rev | DCF rate | Fairness opinion |
|---|---|---|---|---|---|---|---|---|
| 2017-02-14 | Cynosure | Hologic | Medical Devices and Supplies | $1.7B | 21.6x | 3.34x | 14.0%–16.0% | Leerink Partners |
| 2012-04-30 | Gen-Probe | Hologic | Diagnostics / Life Sciences | $3.8B | 16.1x | 5.85x | 7.2% | Morgan Stanley |